Robert Nelsen - 04 Jun 2026 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: SANA
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:25:27 UTC
Prior SEC filing: 01 Aug 2025
Next SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Robert Nelsen

Key filing fact

Robert Nelsen filed Form 4 for Sana Biotechnology, Inc. (SANA) on 05 Jun 2026.

Key facts

This page summarizes Robert Nelsen's Form 4 filing for Sana Biotechnology, Inc. (SANA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 16:25.

Change

Previous filing in this sequence was filed on 01 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001219042 Primary reporting owner

NELSEN ROBERT

Relationship: Director, 10%+ Owner
Address: C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 350, SEATTLE
Signature: /s/ Aaron M. Grossman, Attorney-in-Fact for Robert Nelsen
Signature date: 05 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SANA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +90,000
Change %
Price: $0.000000^*
Shares after: 90,000
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,000
Exercise price: $2.96
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date

SEC remarks

Exhibit List: Ex. 24 - Power of Attorney